Back to top

Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline

Denali Therapeutics ($DNLI) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Multicenter, Open-Label Study to Eva...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Denali Therapeutics Inc. (DNLI)